Objective: To investigate the expressions of D2-40， CK19， galectin-3， VEGF and EGFR in papillary thyroid carcinoma and their clinical significances.
Methods: The expressions of D2-40， CK19， galectin-3， VEGF and EGFR in 38 cases of papillary thyroid carcinoma and 12 cases of thyroid papillary hyperplasia were detected by immunohistochemical staining.
Results: The positive expression rates of D2-40， CK19， Galectin-3， VEGF and EGFR in patients with papillary thyroid carcinoma were all significantly higher than those in patients with thyroid papillary hyperplasia (all P＜0.05). The expressions of D2-40， VEGF and EGFR in papillary thyroid carcinoma with lymph node metastasis were significantly higher than those without lymph node metastasis (P＜0.05). The expressions of CK19 and galectin-3 showed no significant differences between the papillary thyroid carcinomas with and without lymph node metastasis (P＞0.05).
Conclusions: The detection of D2-40， CK19， galectin-3， VEGF and EGFR is helpful to diagnosis and differential diagnosis of papillary thyroid carcinoma and thyroid papillary hyperplasia. The expressions of D2-40， VEGF and EGFR are associated with lymph node metastasis of papillary thyroid carcinoma， which may be useful for predicting whether or not there is cancer  metastasis.